C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.73), $0.01 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $5.39 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.